Minerva Neurosciences, Inc. (NERV)

$0.43

+0.04 (+10.26%)
Rating:
Recommendation:
Neutral
Symbol NERV
Price $0.43
Beta 1.131
Volume Avg. 0.09M
Market Cap 18.370M
Shares () -
52 Week Range 0.331-3.14
1y Target Est -
DCF Unlevered NERV DCF ->
DCF Levered NERV LDCF ->
ROE -284.62% Strong Sell
ROA -72.03% Strong Sell
Operating Margin -
Debt / Equity -9693.10% Strong Sell
P/E -
P/B -24.96 Strong Sell
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest NERV news


Dr. Remy Luthringer
Healthcare
Biotechnology
NASDAQ Global Market

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.